NeuroKey Launch Inoviv recently launched NeuroKey-3, an end-to-end assay for measuring low-level neurodegeneration markers in human plasma, signaling a new service line that complements its targeted proteomics platform and creates cross-sell opportunities with pharma clients focused on neurodegenerative diseases.

VC Backing The investment from Hoxton Ventures and Foresight Group strengthens Inoviv’s financial runway and validation with growth capital, enabling expansion of biomarker workflows and panels and creating a window to approach larger pharma players with broader service offerings.

Targeted Proteomics Inoviv’s platform focuses on targeted proteomics for biomarker test development, aligning with pharmaceutical companies’ needs for precise, quantitative biomarker workflows, which can be positioned as essential for companion diagnostic development and patient stratification.

Geographic Focus Based in London with a compact team, Inoviv can leverage proximity to European pharma hubs for collaborative projects, pilot studies, and regional regulatory engagement, while expanding outreach to global biotech markets through channel partners.

Industry Positioning With a small-to-mid-size profile similar to Advanced Targeting Systems and poised for growth, Inoviv can differentiate through end-to-end assay services, high-sensitivity biomarker measurements, and rapid deployment timelines to win projects from large CROs and mid-sized biotech firms seeking quantitative biomarker solutions.